Cargando…

Potential Cyp3a4-Mediated Drug-Drug Interactions with Ritonavir-Containing Medications in U.S. Patients with Diabetes or Cardiovascular Diseases: An Analysis of Nhanes Data

This cross-sectional study examined the 2015-2019 National Health and Nutrition Examination Surveys (NHANES), which has been used in previous COVID-19 research, to estimate the proportion of adults with diabetes and serious heart conditions (SHCs) at risk of potential drug-drug interactions (pDDIs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Igho-Osagie, Ebuwa, Brzozowski, Kaylen, Jin, Harry, Brown, Jeff, Puenpatom, Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Mosby, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723264/
http://dx.doi.org/10.1016/j.ahj.2022.10.032
_version_ 1784844130858303488
author Igho-Osagie, Ebuwa
Brzozowski, Kaylen
Jin, Harry
Brown, Jeff
Puenpatom, Amy
author_facet Igho-Osagie, Ebuwa
Brzozowski, Kaylen
Jin, Harry
Brown, Jeff
Puenpatom, Amy
author_sort Igho-Osagie, Ebuwa
collection PubMed
description This cross-sectional study examined the 2015-2019 National Health and Nutrition Examination Surveys (NHANES), which has been used in previous COVID-19 research, to estimate the proportion of adults with diabetes and serious heart conditions (SHCs) at risk of potential drug-drug interactions (pDDIs) arising from concomitant use of ritonavir and medications used to treat their comorbid conditions. Medications metabolized through the CYP3A4 pathway were identified as having pDDI with ritonavir, and were categorized as contraindicated, major, moderate, or minor pDDI severity using data sources from University of Liverpool, Lexicomp® and the FDA. Age-stratified prevalence of pDDIs were estimated using U.S. population weights (Table 1). 6.3% and 11.0% of survey participants reported a diagnosis of SHC and diabetes, respectively. pDDIs of any severity were identified in 44.5% of all adults; with 28.4% at risk of major or contraindicated pDDIs. Major or contraindicated pDDIs were observed in 58.1% of adults 60+. Among individuals with diabetes and SHCs, respectively, pDDIs were identified in 83.5% and 90.9% of all adults and in 92.1% and 95.5% of adults 60+. Major or contraindicated pDDIs were identified in 69.5% and 80.2% of adults with diabetes and SHC, respectively; and in 81.4% and 86.0% of individuals with diabetes and SHC aged 60+. This study suggests that majority of U.S. adults with diabetes or SHC are at risk of a major or contraindicated pDDI if treated with ritonavir-containing therapies. Findings highlight the importance of pDDI assessments in determining appropriate COVID-19 therapies, especially for multimorbid and elderly patients.
format Online
Article
Text
id pubmed-9723264
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Mosby, Inc.
record_format MEDLINE/PubMed
spelling pubmed-97232642022-12-06 Potential Cyp3a4-Mediated Drug-Drug Interactions with Ritonavir-Containing Medications in U.S. Patients with Diabetes or Cardiovascular Diseases: An Analysis of Nhanes Data Igho-Osagie, Ebuwa Brzozowski, Kaylen Jin, Harry Brown, Jeff Puenpatom, Amy Am Heart J 0032 This cross-sectional study examined the 2015-2019 National Health and Nutrition Examination Surveys (NHANES), which has been used in previous COVID-19 research, to estimate the proportion of adults with diabetes and serious heart conditions (SHCs) at risk of potential drug-drug interactions (pDDIs) arising from concomitant use of ritonavir and medications used to treat their comorbid conditions. Medications metabolized through the CYP3A4 pathway were identified as having pDDI with ritonavir, and were categorized as contraindicated, major, moderate, or minor pDDI severity using data sources from University of Liverpool, Lexicomp® and the FDA. Age-stratified prevalence of pDDIs were estimated using U.S. population weights (Table 1). 6.3% and 11.0% of survey participants reported a diagnosis of SHC and diabetes, respectively. pDDIs of any severity were identified in 44.5% of all adults; with 28.4% at risk of major or contraindicated pDDIs. Major or contraindicated pDDIs were observed in 58.1% of adults 60+. Among individuals with diabetes and SHCs, respectively, pDDIs were identified in 83.5% and 90.9% of all adults and in 92.1% and 95.5% of adults 60+. Major or contraindicated pDDIs were identified in 69.5% and 80.2% of adults with diabetes and SHC, respectively; and in 81.4% and 86.0% of individuals with diabetes and SHC aged 60+. This study suggests that majority of U.S. adults with diabetes or SHC are at risk of a major or contraindicated pDDI if treated with ritonavir-containing therapies. Findings highlight the importance of pDDI assessments in determining appropriate COVID-19 therapies, especially for multimorbid and elderly patients. Published by Mosby, Inc. 2022-12 2022-12-06 /pmc/articles/PMC9723264/ http://dx.doi.org/10.1016/j.ahj.2022.10.032 Text en Copyright © 2022 Published by Mosby, Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle 0032
Igho-Osagie, Ebuwa
Brzozowski, Kaylen
Jin, Harry
Brown, Jeff
Puenpatom, Amy
Potential Cyp3a4-Mediated Drug-Drug Interactions with Ritonavir-Containing Medications in U.S. Patients with Diabetes or Cardiovascular Diseases: An Analysis of Nhanes Data
title Potential Cyp3a4-Mediated Drug-Drug Interactions with Ritonavir-Containing Medications in U.S. Patients with Diabetes or Cardiovascular Diseases: An Analysis of Nhanes Data
title_full Potential Cyp3a4-Mediated Drug-Drug Interactions with Ritonavir-Containing Medications in U.S. Patients with Diabetes or Cardiovascular Diseases: An Analysis of Nhanes Data
title_fullStr Potential Cyp3a4-Mediated Drug-Drug Interactions with Ritonavir-Containing Medications in U.S. Patients with Diabetes or Cardiovascular Diseases: An Analysis of Nhanes Data
title_full_unstemmed Potential Cyp3a4-Mediated Drug-Drug Interactions with Ritonavir-Containing Medications in U.S. Patients with Diabetes or Cardiovascular Diseases: An Analysis of Nhanes Data
title_short Potential Cyp3a4-Mediated Drug-Drug Interactions with Ritonavir-Containing Medications in U.S. Patients with Diabetes or Cardiovascular Diseases: An Analysis of Nhanes Data
title_sort potential cyp3a4-mediated drug-drug interactions with ritonavir-containing medications in u.s. patients with diabetes or cardiovascular diseases: an analysis of nhanes data
topic 0032
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723264/
http://dx.doi.org/10.1016/j.ahj.2022.10.032
work_keys_str_mv AT ighoosagieebuwa potentialcyp3a4mediateddrugdruginteractionswithritonavircontainingmedicationsinuspatientswithdiabetesorcardiovasculardiseasesananalysisofnhanesdata
AT brzozowskikaylen potentialcyp3a4mediateddrugdruginteractionswithritonavircontainingmedicationsinuspatientswithdiabetesorcardiovasculardiseasesananalysisofnhanesdata
AT jinharry potentialcyp3a4mediateddrugdruginteractionswithritonavircontainingmedicationsinuspatientswithdiabetesorcardiovasculardiseasesananalysisofnhanesdata
AT brownjeff potentialcyp3a4mediateddrugdruginteractionswithritonavircontainingmedicationsinuspatientswithdiabetesorcardiovasculardiseasesananalysisofnhanesdata
AT puenpatomamy potentialcyp3a4mediateddrugdruginteractionswithritonavircontainingmedicationsinuspatientswithdiabetesorcardiovasculardiseasesananalysisofnhanesdata